TP53 and lung cancer: By contrast, Tp53 mutations of endodermal derived TSSC are functionally active last in the series of mutations, as observed in colon, ovary, pancreatic, and lung cancers, and confer a malignant phenotype upon a previously benign tumor with several mutations.